Moghetti P, Tosi F, Castello R, Magnani C M, Negri C, Brun E, Furlani L, Caputo M, Muggeo M
Division of Endocrinology and Metabolic Diseases, University of Verona, Italy.
J Clin Endocrinol Metab. 1996 Mar;81(3):952-60. doi: 10.1210/jcem.81.3.8772557.
To assess whether androgen excess per se might impair insulin action, insulin sensitivity was measured by a two-step (20 and 80 mU/m2.min) hyperinsulinemic euglycemic clamp combined with indirect calorimetry and tracer glucose infusion in 43 women (13 obese and 30 nonobese) with normal glucose tolerance and clinical evidence of increased androgen action (hirsutism and/or polycystic ovary syndrome) as well as 12 age- and body mass index-matched healthy controls. Hyperandrogenic women were studied basally and after 3-4 months of antiandrogen treatment with 3 different drugs: spironolactone (n = 23), flutamide (n = 10), or the GnRH agonist buserelin (n = 10). Six women given spironolactone were also reexamined after 1 yr of therapy. At baseline, insulin-mediated glucose uptake was lower in hyperandrogenic women than in controls (by ANOVA, F = 14.3; P < 0.001). Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing. After antiandrogen therapy, insulin action on glucose metabolism significantly increased for both the patients as a whole (F = 7.4; P < 0.01) and each treatment group separately. However, insulin action remained lower than in controls and showed no further improvement in patients reevaluated after I yr of treatment. Increases in both oxidative and nonoxidative glucose metabolism accounted for the improvement in substrate disposal induced by antiandrogen drugs. The increase in the effectiveness of insulin was greater in the lean subjects, whereas the change was small and not statistically significant in the obese women. Response to treatment was more pronounced in women with nonovarian hyperandrogenism, particularly at the low insulin infusion rate. Endogenous glucose production in hyperandrogenic patients was similar to that in healthy women and was unaffected by therapy. In conclusion, antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used. These data strongly suggest that in women, androgen excess per se contributes to impairment of insulin action.
为了评估雄激素过多本身是否会损害胰岛素作用,我们采用两步法(20和80 mU/m²·min)高胰岛素正常血糖钳夹技术,结合间接测热法和示踪葡萄糖输注,对43名葡萄糖耐量正常且有雄激素作用增强临床证据(多毛症和/或多囊卵巢综合征)的女性(13名肥胖女性和30名非肥胖女性)以及12名年龄和体重指数匹配的健康对照者进行了胰岛素敏感性测量。对高雄激素血症女性进行了基础研究,并在使用3种不同药物进行3 - 4个月抗雄激素治疗后再次研究,这3种药物分别是螺内酯(n = 23)、氟他胺(n = 10)或促性腺激素释放激素(GnRH)激动剂布舍瑞林(n = 10)。6名接受螺内酯治疗的女性在治疗1年后也进行了复查。在基线时,高雄激素血症女性的胰岛素介导的葡萄糖摄取低于对照组(通过方差分析,F = 14.3;P < 0.001)。通过急性GnRH激动剂试验区分,卵巢性和非卵巢性高雄激素血症均存在胰岛素抵抗。抗雄激素治疗后,无论是总体患者(F = 7.4;P < 0.01)还是各个治疗组,胰岛素对葡萄糖代谢的作用均显著增强。然而,胰岛素作用仍低于对照组,且在治疗1年后复查的患者中未显示出进一步改善。氧化和非氧化葡萄糖代谢的增加均导致了抗雄激素药物引起的底物处理改善。胰岛素有效性的增加在瘦人受试者中更大,而在肥胖女性中变化较小且无统计学意义。非卵巢性高雄激素血症女性对治疗的反应更明显,尤其是在低胰岛素输注率时。高雄激素血症患者的内源性葡萄糖生成与健康女性相似,且不受治疗影响。总之,无论使用哪种抗雄激素药物,抗雄激素治疗都能部分逆转与高雄激素血症相关的外周胰岛素抵抗。这些数据强烈表明,在女性中,雄激素过多本身会导致胰岛素作用受损。